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Abstract
Background Attention-deficit/hyperactivity disorder (ADHD)
is a chronic neurobehavioral disorder in children that may
persist into adulthood. Lisdexamfetamine dimesylate (LDX) is
approved in many countries for ADHD treatment in children,
adolescents, and adults.
Objectives Estimate the cost-effectiveness of LDX as a
first- or second-line treatment for adults with ADHD from
the United Kingdom (UK) National Health Service (NHS)
perspective compared with methylphenidate extended
release (MPH-ER) and atomoxetine (ATX).
Methods A 1-year decision-analytic model was developed.
Health outcomes included response, non-response and
inability to tolerate. Efficacy data were obtained from a
mixed-treatment comparison (MTC). Response was a score
of 1 or 2 on the Clinical Global Impression–Improvement
scale. Tolerability was assessed by discontinuation rates
due to adverse events. Utilities were identified via a sys-
tematic literature review. Health care resource use esti-
mates were obtained via a survey of clinicians. Daily drug
costs were estimated from mean doses reported in the trials
used in the MTC. One-way and probabilistic sensitivity
analyses (PSAs) were performed.
Results LDX dominated MPH-ER and ATX; reducing
mean per-patient annual cost by £5 and £200, and
increasing mean quality-adjusted life years (QALYs) by
0.005 and 0.009, respectively. In the PSA, the probability
of cost-effectiveness for LDX vs. MPH-ER and ATX at a
threshold of £20,000 per QALY was 61% and 80%,
respectively.
Conclusions From the perspective of the UK NHS, LDX is
likely to provide a cost-effective treatment for adults with
ADHD. This conclusion may be drawn with more certainty
in comparison with ATX than with MPH-ER.
Keywords ADHD  Lisdexamfetamine  Cost-
effectiveness analysis  Economic evaluation  Attention-
deficit/hyperactivity disorder  Adult
JEL Classification I110
Background
Attention-deficit/hyperactivity disorder (ADHD) is a neu-
rodevelopmental disorder with symptoms of inattention,
hyperactivity, and impulsivity that present in multiple set-
tings [1]. ADHD persists into adolescence and adulthood in
50–60% of childhood cases of ADHD [2]. ADHD is esti-
mated to affect 2–5% of the adult population worldwide,
depending on country, and choice of ADHD diagnostic
criteria [3–6]. Unlike childhood ADHD, gender ratios tend
to be fairly equal in studies of adult ADHD [7–9]. Persistent
inattentive ADHD symptoms in adulthood are significantly
related to an increased risk of long-term work disability [10].
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In the United States (US), the economic burden of ADHD in
adults is estimated to be from $105 billion to $194 billion
per year, of which the largest cost is productivity and
income losses, ranging from $87 billion to $138 billion per
year [11].
Management of ADHD usually includes psychotherapy,
medications, or a combination of both psychotherapy and
pharmacotherapy. In the United Kingdom (UK), methyl-
phenidate (MPH), either extended release (ER) or imme-
diate release (IR), is recommended by the National
Institute for Health and Care Excellence (NICE) Guidance
CG72 to be tried first; if MPH is ineffective or unaccept-
able, atomoxetine (ATX) or dexamfetamine (DEX) may be
tried [12]. ATX or DEX should be considered in adults
unresponsive or intolerant following an adequate trial of
MPH (usually approximately 6 weeks) [12]. Caution
should be exercised when prescribing DEX to those likely
to be at risk of stimulant misuse or diversion [12].
Lisdexamfetamine dimesylate (LDX) is a prodrug; fol-
lowing absorption, LDX undergoes hydrolysis to DEX and
lysine. LDX has received marketing authorizations for the
treatment of ADHD in Australia, Brazil, Canada, Denmark,
Germany, Ireland, Israel, Mexico, Norway, Spain, Sweden,
Switzerland, the UK, and the US. LDX has been shown to
be effective in reducing the symptoms of ADHD in a ran-
domized controlled trial in adults [13], using the ADHD
Rating Scale IV (ADHD-RS-IV) [14]. During the open-label
phase of a modified analogue classroom study of adults with
ADHD, LDX was associated with improvements from
baseline in executive function behavior, using the validated,
self-reported Brown Attention-Deficit Disorder Scale
[15, 16]. In the modified analogue classroom study, LDX
treatment demonstrated efficacy in adults with ADHD who
had significant impairments in ADHD core symptoms and
executive function, as well as efficacy in quality of life as
assessed by Adult ADHD Impact Module (AIM-A) [17]. In
a 10-week randomized, placebo-controlled trial of LDX in
adults with ADHD and clinically significant executive
function deficits, LDX improved AIM-A multi-item domain
scores versus placebo [18]. A randomized, double-blind,
placebo-controlled study using a validated driving simulator
paradigm showed that LDX may reduce driving risks in
young adults with ADHD [19]. Postmarketing survey data
suggest that the rate of non-medical use of LDX is lower
than that for short-acting stimulants and lower than or
equivalent to long-acting stimulant formulations [20]. In a
randomized, double-blind, placebo-controlled, two-way
crossover study conducted in a simulated adult workplace
environment, LDX significantly improved the Permanent
Product Measure of Performance scores versus placebo and
maintained improvement throughout the day from the first
(2 h) to last (14 h) postdose time points versus placebo in
adults with ADHD [21].
The objective of the present study was to estimate the
cost-effectiveness of LDX compared with MPH-ER or
ATX in the treatment of adults with ADHD. The results of
the analysis are presented as the total costs and total
quality-adjusted life years (QALYs) for each drug, as well
as the incremental costs and QALYs for LDX when
compared with MPH-ER or ATX. In addition, the incre-
mental cost-effectiveness ratios (ICERs) for LDX relative
to MPH-ER or ATX are presented and evaluated against an
established cost-effectiveness threshold of £20,000 per
QALY [22]. A comparison of the costs and health out-
comes predicted by the model is intended to aid physicians
and health care decision makers as they make decisions
about efficient use of drugs indicated for adults with
ADHD.
Methods
A decision-tree model was developed in Microsoft Office
Professional 2013 (Excel version 15) to evaluate the cost-
effectiveness of LDX, compared with MPH-ER or ATX,
from the perspective of the UK’s National Health Service
(NHS). Drug treatment is recommended for adults with
ADHD with either moderate or severe levels of impairment
[12]. The selection of comparators was guided by the clinical
guidelines published by NICE [12] and validated by a UK-
based clinical expert. The ER formulation of MPH was
chosen because it is usedmore commonly in clinical practice
in the UK than the IR formulation (Shire data on file; IMS
Database, March 2015) and MPH-ER has a broader clinical
evidence base, reflected by a larger number of clinical trials
in adults (see Online Resource 1). Non-pharmacological
interventions were included in the analysis as part of the non-
drug costs and were assumed to vary for responders and non-
responders to drug therapy. There is no evidence to suggest
that any of the drug treatments would result in a reduction in
the amount or type of non-pharmacological or behavioral
intervention required for those responding to therapy or for
those not responding to therapy.
The target population for the cost-effectiveness analysis
was adults with ADHD, which reflects the anticipated
therapeutic licensed indication for LDX in both adult
continuers (i.e., adults whose ADHD was diagnosed during
childhood and adolescence) and de novo adult patients (i.e.,
adults with ADHD not diagnosed during childhood or
adolescence). The health outcomes included were ‘‘toler-
ate’’, ‘‘unable to tolerate’’, ‘‘response’’ and ‘‘non-response’’
(Fig. 1). The impact of using LDX as an alternative to
MPH-ER or ATX in terms of costs and health outcomes
was estimated in the model based on the number of patients
who achieved response to treatment and those who did not,
including those who discontinued due to adverse events.
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Costs and utilities corresponding to the patients’ health
states were assigned to each of these patients.
The base-case analysis evaluated direct medical costs and
health-related quality of life associated with 1 year of
treatment, including the initial 28-day drug titration period.
A time horizon of up to 5 years was examined as a sensitivity
analysis with an annual discounting rate of 3.5% applied to
both costs and benefits. The modeling framework and key
assumptions, including the 1-year time horizon, were adap-
ted from the health technology assessment model used in an
earlier assessment of ADHD drugs by NICE [23].
The uncertainty in the ICER estimate was explored by
one-way sensitivity analysis and probabilistic sensitivity
analysis (PSA). Quality control of model programming and
verification of all input data with original sources was
performed according to a prespecified test plan by health
economists who were not involved in the model develop-
ment. Key model assumptions were assessed for face
validity by a UK clinician with extensive experience in
treating and research in adults with ADHD, and by an
independent health economics expert.
Model assumptions
The following assumptions were made in the base-case
analysis.
Adult continuers or de novo adult patients enter the
model when they initiate a course of treatment with LDX,
MPH-ER or ATX.
Patients begin titration lasting 28 days, during which the
optimal dose of treatment is reached (ATX may require a
longer titration period, which is tested in the sensitivity
analysis).
Patients who experience intolerable side effects dis-
continue treatment in the middle of the titration period
(i.e., after 14 days on treatment). For patients who dis-
continue treatment during the titration period, utilities and
costs during the titration period (28 days) are represented
by a 50%/50% mix of the responder and non-responder
utility values, and a 50%/50% mix of the responder and
non-responder non-drug costs, respectively. This approach
was based on the assumption that, on average across dif-
ferent treatments, patients who discontinue responded half
way through the first month (consistent with the assump-
tion by King et al. [23] in the UK Health Technology
Appraisal of ADHD drugs in children and adolescents).
Alternative assumptions were explored in which these
patients were assumed to have the same utility during their
titration period as responders and as non-responders.
Patients who discontinue treatment due to intolerable
side effects do not initiate additional pharmacological
treatment. Those who discontinue, the same as non-re-
sponders, are assumed to receive behavioral therapy. This
assumption was made largely due to lack of relevant
clinical data for follow-up therapies and the fact that in the
model, these therapies would be the same in both the LDX
and the comparator arms, hence not adding any differen-
tiation to the model results. The patients who discontinue
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Fig. 1 Model Structure. ADHD attention-deficit/hyperactivity disor-
der, LDX lisdexamfetamine, NT no pharmacological treatment.
Reproduced from Zimovetz, E.A., Beard, S.M., Hodgkins, P. et al.
CNS Drugs (2016) 30:985. doi:10.1007/s40263-016-0354-3, under
the terms of the Creative Commons Attribution-NonCommercial 4.0
International License (http://creativecommons.org/licenses/by-nc/4.0/
), with minor amends reflecting the change in study population from
children/adolescents to adults.
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as non-responders for the remainder of the 1-year model
time horizon.
At the end of the titration period, non-responding
patients discontinue treatment without initiating any further
pharmacological treatment and are assigned the non-re-
sponse costs and utilities for the titration period and
throughout the model’s remaining time horizon.
Patients who respond to treatment at the end of the titration
period remain on treatment throughout the remainder of the
model’s time horizon, maintaining their level of response.
Patients who responded to and tolerated treatment are
assumed to be adherent and persistent on treatment over the
time horizon of the model, as was generally observed in the
pivotal trials. This assumption is consistent with that made
in the health technology assessment model presented by
King et al. [23].
This dichotomous response framework was adapted
from the model developed by King et al. [23] as part of the
UK Health Technology Appraisal of ADHD drugs in
children and adolescents.
Clinical input parameters applied in the model were
estimated via a Bayesian network meta-analysis (NMA) of
trials in adults with ADHD.
Costs and outcomes are not discounted in the base-case
analysis, given the time horizon of 1 year.
Model parameter inputs
Efficacy and safety
The economic model applied clinical input parameter values
estimated via a BayesianNMAof trials in adults withADHD.
A systematic literature review was conducted to identify
clinical evidence for treatments of ADHD. The review was
conducted in accordance with a prespecified literature review
protocol. The following six medical databases were searched:
MEDLINE, Embase, Cochrane library, PsychINFO,
CINAHL and Science Citation Index. Grey literaturewas also
searched, including proceedings from relevant conferences.
Studies were selected independently by two reviewers, with
discrepancies resolved through consensus or consultationwith
a third reviewer if a consensus could not be reached. The
inclusion and exclusion processes were thoroughly docu-
mented, including completion of the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA)
diagram (available in Online Resource 1).
The NMA was performed in accordance with recom-
mendations from NICE’s Decision Support Unit and Inter-
national Society for Pharmacoeconomics and Outcomes
Research, and used a mixed-treatment comparison (MTC)
framework [24, 25]. A detailed description of the methods
used for the MTC is presented in Online Resource 1.
The Clinical Global Impression–Improvement (CGI–I)
scale was chosen as the measure of response to treatment
based on data reported in most of the clinical trials inclu-
ded in the MTC; clinical response was measured as a score
of 1 (much improved) or 2 (improved) on the clinician-
rated CGI–I scale.
None of the trials of ATX included in the MTC reported
response data defined using the CGI–I scale. Therefore, an
imputation analysis was conducted to estimate CGI–I
response for ATX based on ADHD-RS-IV total score
change from baseline. The imputation analysis was based
on methods first presented by Goodman et al. [26], which
involved the estimation of the proportion achieving CGI–I
response based on the ADHD-RS-IV change from baseline.
Using data from trials of LDX that reported both ADHD-
RS-IV change from baseline and CGI–I response, quadratic
regression was used to model the relationship between
these quantities. Then the relationship identified via the
quadratic regression was used to identify a cutoff for
ADHD-RS-IV change, such that ADHD-RS-IV changes
larger than the cutoff corresponded to CGI–I response. The
distribution of the ADHD-RS-IV change in the ATX trial
was identified using the mean and standard deviation under
the assumption of normality. Then the cutoff was applied
to this distribution to identify the proportion with CGI–I
response. Alternative methods to determine the cutoff were
evaluated also, and the imputation method was validated
using other trials reporting both ADHD-RS-IV change and
CGI–I response. Table 1 presents the Bayesian MTC
results with ATX data derived using a quadratic regression
imputation analysis (see Online Resource 1).
Withdrawal rates were based on discontinuations due to
adverse events as reported within the trials and were esti-
mated via an MTC. Table 2 presents the Bayesian MTC
results for rates of withdrawals due to adverse events.
The economic analysis did not incorporate incidences of
individual adverse events, nor did it include the corre-
sponding costs and disutilities associated with these events
Table 1 Primary base-case analysis: relative risks for treatment
response (drug vs. placebo)
Treatment Relative risk (95% CrI) Placebo risk (95% CrI)
LDX 2.14 (1.71–2.57) 0.3084 (0.264–0.353)
ATX 1.65 (1.00–2.32)
MPH-ER 1.84 (1.44–2.23)
ADHD-RS-IV ADHD Rating Scale IV, ATX atomoxetine, CrI credible
interval, CGI–I Clinical Global Impression–Improvement, LDX lis-
dexamfetamine dimesylate, MPH-ER methylphenidate extended
release
Response was defined by a rating of 1 or 2 in CGI–I score. Quadratic
regression extrapolation method (random effects model, combined
doses) was used for the ATX arm, using only the ADHD-RS-IV
scores in extrapolating the CGI–I-based response for ATX
E. A. Zimovetz et al.
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because of similar rates of mild or moderate side effects of
the comparators and because more severe adverse events
would lead to treatment discontinuation and would be
accounted for in the model through discontinuation. A
12-month open-label, single-arm study demonstrated that
LDX has a safety profile consistent with long-acting
stimulant use [27].
Health-state utilities
A systematic review of economic literature in ADHD was
conducted to identify utility values. The systematic litera-
ture review was performed in accordance with a prespec-
ified protocol; searches were conducted via electronic
medical databases and specified websites. A detailed
description of the systematic review of the economic lit-
erature is included in Online Resource 2. The mean utility
values used in the economic analysis were 0.76 for
responders and 0.68 for non-responders (95% confidence
intervals, not reported for either) [28]. These utility values
were obtained from a web-based survey using EuroQol
5-Dimensions 3 Levels (EQ-5D-3L) questionnaires com-
pleted by adults with ADHD [28]. The rationale for
selecting the Mitsi et al. [28] study as the source of the
utility values in the model was twofold. First, this study
complied with the NICE reference case, which states that
measurement of changes in health-related quality of life
should be reported directly by patients, the value of
changes in patients’ health-related quality of life should be
based on public preferences using a choice-based method,
and the EQ-5D is the preferred measure of health-related
quality of life in adults [22]. Second, the study reported
utility values within a dichotomous framework of response
and no response, which was appropriate for the health
states used in the economic analysis.
Resource use and costs
The systematic review of economic literature in ADHD
highlighted the data gap in published cost and resource use
estimates appropriate for inclusion in the current economic
analysis. Health care resource utilization estimates associ-
ated with response and non-response were obtained from a
survey of clinicians treating patients with ADHD in the UK
at the time of the study. The sample consisted of 60 spe-
cialists, all psychiatrists, with 83% based in England and
17% based in Scotland. The survey methods are presented
in Online Resource 3.
Unit costs of health care resources from the National Ref-
erence Costs schedules were then applied to these resource
utilization estimates to calculate the costs associated with
responders and non-responders. The non-drug costs translated
to a per-month (28 days) cost of £115.84 for each responder
and to £337.82 for each non-responder (Table 3).
Drug unit costs were obtained from the British National
Formulary. The analysis was based on the prices for LDX of
£2.08 (for a 30-mg tablet), £2.45 (for a 50-mg tablet) and
£2.97 (for a 70-mg tablet); the prices for MPH-ER of £1.04
(for an 18-mg tablet), £1.23 (for a 27-mg tablet) and £1.42
(for a 36-mg tablet); the prices forATXof £1.90 (for 10-, 18-,
25-, 40-, and 60-mg tablets) and £2.53 (for an 80-mg tablet)
[32]. Drug costs were calculated using the weighted average
doses and per-milligram drug costs. The average doses were
derived from trials used in the MTC to calculate response
rates. Each per-milligram cost was based on the cost of a
pack with the tablet size closest to the given mean dose.
Sensitivity analyses
A number of sensitivity analyses were performed to
explore the robustness of the economic model. These
included a deterministic one-way sensitivity analysis and a
PSA.
One-way sensitivity analysis
In the deterministic one-way (univariate) sensitivity anal-
ysis, the stability of the model’s results was tested over a
range of input data values, whereby parameters were
changed from their base-case values one at a time, with all
other parameters remaining constant (Table 4). The fol-
lowing summarizes the variables considered in the one-
way sensitivity analysis.
Efficacy
In the base-case analysis, the model applied mean relative
risks of treatment response for each drug versus placebo
estimated via a Bayesian NMA of trials in adults with
ADHD. The sensitivity analysis applied the lower and
upper credible interval values.
Safety
In the base-case analysis, to incorporate tolerability, the
model applied mean discontinuation rates due to adverse
Table 2 Relative risks for discontinuation due to adverse events
(drug vs. placebo)
Treatment Relative risk (95% CrI) Placebo risk (95% CrI)
LDX 3.21 (0.93–7.90) 0.0443 (0.035–0.053)
ATX 2.67 (1.68–4.13)
MPH-ER 2.76 (1.83–4.07)
ATX atomoxetine, CrI credible interval, LDX lisdexamfetamine
dimesylate, MPH-ER methylphenidate extended release
A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with…
123
events. The credible intervals for discontinuation rates
estimated by the NMA were unusually wide due to a low
rate of adverse events observed in the clinical trials. The
sensitivity analysis, therefore, used values calculated as the
mean discontinuation rate plus (or minus) one standard
deviation.
Table 3 Resource use and
costs applied in the base-case
analysis
Resource item Unit cost Units per year (SD) Average cost per year
Responders
Psychiatrista £266.27 3.34 (2.39) £889.34
Psychologistb £201.38 1 (NA) £201.38
GPc £37.00 3.30 (2.43) £122.10
Nursed £44.00 3.72 (4.97) £163.68
Blood pressuree £12.14 2.92 (2.15) £35.45
Weight measuremente £12.14 2.94 (2.44) £35.70
Blood testf £3.00 1.40 (1.71) £4.20
ECGg £52.00 0.92 (1.22) £47.84
EEGh £72.00 0.08 (0.33) £5.76
Allergy testi £5.00 0.09 (0.49) £0.45
Total (per 28 days) – – £1506 (£115.84)
Non-responders
Psychiatrista £266.27 6.83 (4.02) £1818.62
Psychologistb £201.38 9.67 (5.82) £1947.34
GPc £37.00 5.83 (3.89) £215.71
Nursed £44.00 5.38 (6.13) £236.72
Blood pressuree £12.14 3.62 (2.44) £43.95
Weight measuremente £12.14 3.36 (2.54) £40.80
Blood testf £3.00 1.98 (2.13) £5.94
ECGg £52.00 1.36 (1.63) £70.72
EEGh £72.00 0.15 (0.50) £10.80
Allergy testi £5.00 0.21 (0.66) £1.05
Total (per 28 days) – – £4392 (£337.82)
ECG electrocardiogram, EEG electroencephalogram, GP general practitioner, NA not applicable, NHS
National Health Service, SD standard deviation
a Source: Curtis (2013): unit costs of health and social care 2013 (15.7 Consultant: psychiatric—per face-
to-face contact. Excludes cost of qualifications) [29]. Inflated to 2015 prices using the hospital and com-
munity health services (HCHS) index [30]
b Source: Department of Health (2015): national schedule of reference costs year: 2014–15—all NHS trusts
and NHS foundation trusts—outpatient attendances data (656 clinical psychology) [31]
c Source: Curtis and Burns (2015): unit costs of health and social care 20,155 (10.8b general practitioner—
unit costs. Per-patient contact lasting 11.7 min. Cost excludes cost of qualification) [30]
d Source: Curtis and Burns (2015): unit costs of health and social care 2015 [10.4 nurse specialist
(community)—unit costs. Per hour. Cost excludes cost of qualification] [30]
e Source: Curtis and Burns (2015): unit costs of health and social care 2015 [10.6 nurse (GP practice)—unit
costs. Based on £47 per hour and consultation lasting 15.5 min. Cost excludes cost of qualification] [30]
f Source: Department of Health (2015): national schedule of reference costs year: 20,145—NHS trusts and
NHS foundation trusts: directly accessed: pathology services. DAPS05—Hematology [31]
g Source: Department of Health (2015): national schedule of reference costs year: 2014–15—NHS trusts
and NHS foundation trusts: direct access: diagnostic services EY51Z—electrocardiogram monitoring and
stress testing [31]
h Source: Department of Health (2015): national schedule of reference costs—year 2014–15—NHS trusts
and NHS foundation trusts: direct access: diagnostic services. AA33C—conventional EEG, EMG or nerve
conduction studies with length of stay 2 days or less, 19 years and over [31]
i Source: Department of Health (2015): national schedule of reference costs year: 2014–15—NHS trusts
and NHS foundation trusts: directly accessed pathology services. DAPS06—immunology [31]
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Table 4 Univariate sensitivity analysis input parameter estimates
Input parameter Base-case analysis Sensitivity analysis
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Utility values
In the base-case analysis, the model applied health-state
utility estimates reported by Mitsi et al. [28]. This study’s
methodology was considered most compliant with the
NICE reference case; however, the reported utility value
for responders might be slightly lower than expected for
adults with ADHD who are otherwise healthy. The sensi-
tivity analysis applied alternative published utility values
reported by Matza et al. [33], in which the utility value for
responders was higher (0.82 vs. 0.76) and the utility value
for non-responders was the same as in the study by Mitsi
et al. [28].
Resource use estimates
In the base-case analysis, the model applied estimated
resource use for responders and non-responders derived via
a survey of UK-based practicing clinicians. In the sensi-
tivity analysis, the cost for responders was increased by one
additional visit to a psychiatrist and one additional visit to a
GP (resulting in an increase of*20% in the monthly non-
drug cost for responders).
Time horizon
The base-case analysis assumed a time horizon of 1 year,
which was extended to 5 years, without changing the
model assumptions, in a sensitivity analysis.
Drug-costing method
The base-case analysis used a method of drug costing that
used the average daily doses from clinical trials in calcu-
lating the daily drug costs. The sensitivity analysis
explored the effect of applying the drug costs calculated
based on real-world drug utilization, rather than on the
drug usage reported in the clinical trials.
Length of titration period for ATX
Response in the model was assessed at the end of the
titration period, which was represented by 28 days. The
base-case analysis assumed the same length of the titration
period for LDX and ATX. The sensitivity analysis explored
the differential time to response that was seen with patients
on ATX (i.e., the antidepressant-like response typically
seen after 8–12 weeks on treatment).
Scenario analyses exploring a longer model time
horizon and a different non-responder resource use
The stability of the model’s results was tested over a longer
time horizon and alternative assumptions about non-re-
sponder resource use. Under this analysis, the model time
horizon was extended to 5 years and non-responder annual
resource use was adjusted to reflect the lower frequency of
follow-up expected in the longer term based on possible
decline over time of symptoms of ADHD (decreased by
Table 4 continued
Input parameter Base-case analysis Sensitivity analysis
Value Source Value Source
Length of
titration periodd
LDX 28 days Assumption 28 days Assumption
MPH-ER 28 days 28 days
ATX 28 days 84 days
ATX atomoxetine, CRI credible interval, LDX lisdexamfetamine dimesylate, MPH-ER methylphenidate extended release, MTC mixed-treatment
comparison, NMA network meta-analysis, RR response rate, SD standard deviation, UK United Kingdom
a Differences in drug costs between Method A and Method B are applicable only to the post titration costs. The same costs for the titration period
were used in both methods
b Weighted average doses from trials (51.5 mg for LDX, 50.93 mg for MPH-ER and 80 mg for ATX) were multiplied by the costs per milligram
of the corresponding drug. Each per-milligram cost was based on the cost of the package with a tablet size closest to a given average dose
c Real-world daily UK consumption estimates (1.62 tablets per day for MPH-ER and 1.39 tablets per day for ATX) were derived from the IMS
databases [Shire Pharmaceuticals: IMS Midas and IMS Prescription Databases 2013. (2014)]. For LDX, real-life usage was based on an
assumption (1 tablet per day)
d Variable length of titration period is applicable only to analyses containing ATX. The assumption of 84 days as the length of the titration
period for ATX reflects that, in a proportion of ATX patients, response may be achieved gradually over approximately 3 months
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one visit to psychiatrist, one visit to psychologist and one
visit to GP). This scenario was run twice—using the base-
case utility inputs from Mitsi et al. [28] and then using the
alternative utility inputs from Matza et al. [33].
Additional scenario analyses
Alternative assumptions were explored in which patients
who discontinue were assumed to have the same utility
during their titration period as responders and then as non-
responders, rather than a 50%/50% mix of the responder
and non-responder utilities assumed in the base-case
analysis.
Additional analysis was conducted to compare LDX
with MPH-IR. As no relevant clinical trials of MPH-IR
were identified for inclusion in the MTC, the analysis was
performed assuming the same efficacy for MPH-IR as for
MPH-ER. The basis for this assumption was the result of
the trial in children, which showed little difference in
efficacy between the ER and IR formulations [34]. The
analysis was based on the price of MPH-IR of £0.36 per
20-mg tablet [13]. The average dose for the titration period
was assumed to be the same as for MPH-ER (36.98 mg per
day), and the average dose for the post-titration period
(82 mg per day) was taken from a safety trial of MPH-IR in
adults with ADHD identified by the systematic review [35].
Probabilistic sensitivity analysis
Uncertainty in model input parameters was examined in the
PSA, wherein all input parameters, apart from drug costs,
which were known with certainty, were simultaneously
varied using prespecified distributions reflecting the
uncertainty about their true values. Five thousand repeated
model simulations were performed. Non-drug costs for
responders and non-responders were simulated using the
Gamma distribution. Parameters for the Gamma distribu-
tion were derived using the mean and standard error of the
unit of the resource use obtained from the survey. Utility
values were simulated using the uniform distribution with a
±10% variation. Clinical parameter values were not varied
using prespecified distributions. Instead, these were simu-
lated from the posterior distributions using the mean and
standard deviation from 50,000 posterior samples from the
Bayesian MTC, assuming a normal distribution based on




The results suggested that use of LDX was a dominant
strategy compared with MPH-ER [i.e., it was less expen-
sive (-£4.78) and more effective (0.005)]. Total 1-year
per-patient costs for LDX and MPH-ER were £3379 and
£3384, respectively, and total 1-year QALYs, out of a
maximum possible 1, were 0.724 for LDX and 0.718 for
MPH-ER (Table 5).
LDX vs. ATX
The results suggested that use of LDX was a dominant
strategy compared with ATX [i.e., it was less expensive
(-£199.93) and more effective (0.009)]. Total 1-year costs
per patient for LDX and ATX were £3379 and £3579,
respectively, and total 1-year QALYs, out of a maximum




Table 6 and Fig. 2 summarize the results of the one-way
sensitivity analysis. The results of the model were found to
be robust to changes in most of the model input parameter
values for both scenarios, apart from changes in discon-
tinuation rates due to adverse events for the MPH-ER
comparison. The model was most sensitive to the increase
Table 5 Base-case analysis results (per patient)
Scenario Comparisons Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£ per QALY) INMB (£)a
A MPH-ER vs 3384 0.718 -4.78 0.005 LDX dominant 109
LDX 3379 0.724
B ATX vs 3579 0.715 -199.93 0.009 LDX dominant 381
LDX 3379 0.724
ATX atomoxetine, ICER incremental cost-effectiveness ratio, INMB incremental net monetary benefit, LDX lisdexamfetamine dimesylate, MPH-
ER methylphenidate extended release, QALY quality-adjusted life year
a At £20,000 per QALY
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Table 6 Univariate sensitivity analysis results (per patient)
Parameter Scenario A: LDX vs. MPH-ER Scenario B: LDX vs. ATX
Base-case resultsa QALYs: 0.005 QALYs: 0.009
Costs: -£4.78 Costs: -£199.93
ICER: Dominant ICER: Dominant
INMBb: £109 INMB: £381
Efficacy (lower CrI bound) QALYs: 0.004 QALYs: 0.012
Costs: -£5.83 Costs: -£270.80
ICER: Dominant ICER: Dominant
INMB: £88 INMB: £508
Efficacy (upper CrI bound) QALYs: 0.007 QALYs: 0.004
Costs: -£7.82 Costs: -£82.34
ICER: Dominant ICER: Dominant
INMB: £142 INMB: £169
Safety—rates of discontinuation
due to adverse events (mean
-1SD)
QALYs: 0.008 QALYs: 0.012
Costs: -£69.85 Costs: -£271.24
ICER: Dominant ICER: Dominant
INMB: £232 INMB: £511
Safety—rates of discontinuation
due to adverse events (mean
?1SD)
QALYs: 0.002 QALYs: 0.005
Costs: £75.24 Costs: -£112.48
ICER: £43,525 per QALY ICER: Dominant
INMB: -£41 INMB: £221
Health-state utility; from Matza
et al. [33]
QALYs: 0.009 QALYs: 0.016
Costs: -£4.78 Costs: -£199.93
ICER: Dominant ICER: Dominant
INMB: £188 INMB: £516
Resource utilization; responder
costs increased by one additional
visit to psychiatrist and one to
GP
QALYs: 0.005 QALYs: 0.009
Costs: £15.06 Costs: -£165.68
ICER: £2878 per QALY ICER: Dominant
INMB: £90 INMB: £346
Time horizon 5 years QALYs: 0.025 QALYs: 0.044
Costs: -£147.12 Costs: -£1050.09
ICER: Dominant ICER: Dominant
INMB: £652 INMB: £1921
Drug-costing method; dosing
taken from observational data
QALYs: 0.005 QALYs: 0.009
Costs: £39.75 Costs: -£434.37
ICER: £7593 per QALY ICER: Dominant
INMB: £65 INMB: £615
Length of titration period; ATX





ATX atomoxetine, CrI credible interval, GP general practitioner, ICER incremental cost-effectiveness ratio, INMB incremental net monetary
benefit, LDX lisdexamfetamine dimesylate, MPH-ER methylphenidate extended release, NA not applicable, QALY quality-adjusted life year, SD
standard deviation
a In the base-case analysis, the following values were used for the parameters examined in the sensitivity analysis: utility = 0.76 (responder),
0.68 (non-responder); per-month non-drug costs = £115.84 (responder), £337.82 (non-responder); time horizon = 1 year; per-month drug
costs = £70.90 (LDX), £56.24 (MPH-ER), £71.03 (ATX); length of ATX titration period = 4 weeks
b The INMB was calculated for the threshold of £20,000 per QALY using the following formula: INMB = incremental QALYs 9 thresh-
old - incremental cost
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of one standard deviation in the discontinuation rate due to
adverse events. For the MPH-ER comparison, such an
increase changed the base-case result from LDX being
dominant to LDX being not cost-effective (£43,525 per
QALY at a threshold of £20,000 per QALY). For the ATX
comparison, the base-case result did not change under this
scenario, with LDX remaining a dominant strategy.
For the MPH-ER comparison, the model was also sen-
sitive to changes in drug costs, with base-case result
changing from LDX being dominant to LDX being cost-
effective at £7593 per QALY, and to changes in the
resource use for responders, with base-case result changing
from LDX being dominant to LDX being cost-effective at
£2878 per QALY, under the willingness-to-pay threshold
of £20,000 per QALY. For the ATX comparison, the model
was not sensitive to these alternative values.
Scenario analyses exploring a longer model time horizon
and a different non-responder resource use
For the ATX comparison, the results did not change their
direction, and LDX remained a dominant strategy; for the
MPH-ER comparison, the results for LDX changed slightly
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QALY (using utility values from the study by Mitsi et al.
[28]) and £273 (using utility values from the study by
Matza et al. [33]), under the £20,000 per QALY willing-
ness-to-pay (Table 7).
Additional scenario analyses
Alternative assumptions around the utility weight for
patients who discontinue during the titration period had
very little impact on the ICERs. The mean incremental
QALY for the comparison versus MPH-ER changed from
0.0052 to 0.0054 per person, when the responder utility
was used in the titration period for those who discontinue.
When the nonresponder utility was used, the mean incre-
mental QALY for the same comparison changed from
0.0054 to 0.0050 per person.
The results of the analysis vs. MPH-IR suggested that
LDX was cost-effective under the threshold of £20,000 per
QALY. The ICER was estimated at £19,362 per QALY,
with mean incremental QALYs and costs per person of
0.005 and £101.35, respectively.
Probabilistic sensitivity analysis
Table 8 and Fig. 3 present the results of the PSA. For the
LDX versus MPH-ER comparison, the results suggested a
61% probability that LDX was cost-effective when com-
pared with MPH-ER at a threshold of £20,000 per QALY.
The results suggested that LDX had an 80% probability of
being cost-effective against ATX at the willingness-to-pay
threshold of £20,000 per QALY.
Discussion
Our economic analysis used the results of a Bayesian MTC
of efficacy to assess the cost-effectiveness of LDX when
compared with MPH-ER or ATX in the treatment of adults
Table 7 Scenario analysis results (per patient)
Parameter Scenario A: LDX vs. MPH-ER Scenario B: LDX vs. ATX
Scenario analysisa, with health-state utility from Mitsi et al. [28] QALYs: 0.025 QALYs: 0.044
Costs: £12.04 Costs: -£775.38
ICER: £477 per QALY ICER: Dominant
INMBb: £493 INMB: £1646
Scenario analysisa, with health-state utility from Matza et al. [33] QALYs: 0.044 QALYs: 0.076
Costs: £12.04 Costs: -£775.38
ICER: £273 per QALY ICER: Dominant
INMB: £871 INMB: £2300
ATX atomoxetine, ICER incremental cost-effectiveness ratio, INMB incremental net monetary benefit, LDX lisdexamfetamine dimesylate, MPH-
ER methylphenidate extended release, QALY quality-adjusted life year
a In the scenario analysis, the following alternative values to the base-case analysis were used: per-month non-drug costs = £115.84 (responder),
£299.00 (non-responder); time horizon = 5 years
b The INMB was calculated for the threshold of £20,000 per QALY using the following formula: INMB = incremental QALYs 9 thresh-
old - incremental cost































ATX atomoxetine, CrI credible interval, ICER incremental cost-effectiveness ratio, LDX lisdexamfetamine dimesylate, MPH-ER methylphe-
nidate extended release, QALY quality-adjusted life year
a At £20,000 per QALY
b The CrIs for probabilistic ICER estimates are not defined when these estimates are spread over multiple quadrants of the cost-effectiveness
plane
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with ADHD. The base-case results showed that LDX was a
dominant strategy when compared with MPH-ER; however,
there was some uncertainty in this result, with the PSA
estimating a 61% probability of LDX being cost-effective
vs. MPH-ER under a £20,000 willingness-to-pay threshold.
One-way sensitivity analysis results revealed that the model,
when comparing LDX with MPH-ER, was most sensitive to
increase in discontinuation rates due to adverse events. From
the MTC outputs, rates of discontinuation due to adverse
events had fairly broad credible intervals largely translating
from small sample sizes for patients who discontinue in the
trials used in the MTC (Table 2 and Online Resource 1).
LDX was a dominant strategy when compared with ATX.
Sensitivity analyses confirmed the robustness of this result,
showing an 80% likelihood of LDX being cost-effective
relative to ATX when applying probabilistic methods. One-
way sensitivity analysis results revealed no changes in the
model results, when comparing LDX with ATX, for any of
the variables examined.
The present economic analysis, to the authors’ knowl-
edge, is the first published study on the cost-effectiveness
of pharmacotherapy in the adult ADHD population. A
recent systematic review published in 2012 identified no
published studies on the cost-effectiveness of
pharmacotherapy in the adult ADHD population, compar-
ing stimulants, non-stimulants or adjuvant therapy [36].
Our model found that LDX is cost-effective relative to
MPH-ER or ATX and would provide a good additional
stimulant option. The inclusion of a new cost-effective
treatment option for adults with ADHD could allow for
patients’ individual needs and preferences to be taken into
consideration. Having multiple stimulant and non-stimu-
lant treatment options available is likely to contribute to a
reduction in the overall burden of ADHD.
The choice of a short time frame for this analysis was
driven by the lack of long-term data needed for a longer
model time horizon. The chosen time frame requires
minimal extrapolation of the short-term data from the trials
(duration of trials used in the MTC ranged from 4 to
34 weeks), thus minimizing the uncertainty. The shorter
time horizon can also be justified by the current clinical
guidelines, which recommend that treatment for adults with
ADHD should be reviewed at least annually [12]. The one-
way sensitivity analysis and the scenario analyses showed
that extending the model time horizon to 5 years and
changing non-response resource use did not have much
impact on the cost-effectiveness results.
This modeled assessment had some limitations. First,
the MTC was limited by the number of prior studies, which
led to the need for an imputation analysis and limited the
precision of the estimates. Although the imputation anal-
ysis was used to produce conservative point estimates of
the relative risk of CGI–I response, the estimates of vari-
ability from that analysis do not account for the additional
variability due to the imputation. Hence, although the point
estimates are likely to be conservative, the corresponding
credible intervals and confidence intervals should be
interpreted with caution. Generally, indirect treatment
comparisons enable us to compare treatments not otherwise
compared in a head-to-head clinical trial, but they do not
equate to the same level of evidence as direct (head-to-
head) comparisons. The results of the current MTC were
generally consistent with the results of the pivotal trials,
and no statistical evidence of heterogeneity across trials
was found. Second, due to lack of data, the study did not
consider any treatment for non-responders and assumed
these patients discontinued drug therapy. In real-world
clinical practice, such patients may receive one of the other
comparators or off-label medications (e.g. bupropion,
clonidine, modafinil or imipramine) or combination treat-
ments [12]. Neither did it consider dose reduction if side
effects became troublesome. Third, the utility data for
intolerable side effects were not based on disutility data of
individual side effects leading to discontinuation, but were
estimated in the model as a 50%/50% mix of the responder
and non-responder utility values. However, alternative
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Fig. 3 Cost-effectiveness acceptability curves. a LDX vs. MPH-ER.
b LDX vs. ATX. ATX atomoxetine, LDX lisdexamfetamine dimesy-
late, MPH-ER methylphenidate extended release, QALY quality-
adjusted life year
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discontinue during the titration period had very little
impact on the ICERs. Fourth, the model did not consider
real-life medication compliance, again, due to the lack of
data, this time on the relationship between adherence to
therapy and symptom reduction. Finally, the study was
conducted from the UK NHS perspective and did not
include the broader societal perspective, which is an
important cost driver in the overall cost burden of ADHD.
Taking into account costs associated with the societal
perspective likely would result in an even lower ICER for
LDX, given a potential cost-offset.
There is limited evidence on the cost-effectiveness of
medication to treat ADHD in adults, as well as long-term
cost-effectiveness of pharmacotherapies in ADHD. To
better inform payers about the economic value of existing
medications, future studies should consider identifying
subgroups that may have heterogeneous responses to dif-
ferent treatments and expanding the time horizon to
incorporate long-term outcomes [36].
Conclusions
This study suggests that LDX is likely to dominate both
MPH-ER and ATX as a therapy for adult patients with
ADHD (both previously treated and untreated patients);
i.e., total costs are expected to be lower and outcomes
(QALYs) are expected to be improved with LDX therapy
compared with both MPH-ER and ATX therapy. These
results, particularly for the comparison versus MPH-ER,
must be seen in light of some uncertainty detected by the
PSA. The presented model adds to the health economic
information available for policymakers and to general
considerations in economic modeling.
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